重症虚血肢治療の世界市場

重症虚血肢治療の世界市場は2030年までに81億米ドルに達する見込み

2024年に56億米ドルと推定される重症虚血肢治療の世界市場は、2024年から2030年にかけてCAGR 6.5%で成長し、2030年には81億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである創傷ケア用ドレッシングは、CAGR 4.8%を記録し、分析期間終了時には28億米ドルに達すると予想されます。生物製剤セグメントの成長率は、分析期間中CAGR 8.2％と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 9.8％で成長予測

米国の重症虚血肢治療市場は、2024年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.3％と6.2％と予測されています。欧州では、ドイツがCAGR 4.2%で成長すると予測されています。

世界の重症虚血肢治療市場- 主要動向と促進要因のまとめ

なぜ重症虚血肢治療の需要が増加しているのか？末梢動脈疾患患者の増加を理解する

世界の重症虚血肢（CLI）治療市場は、末梢動脈疾患（PAD）、糖尿病、心血管疾患の有病率の増加により急成長を遂げています。CLIはPADの重症型で、下肢の血流低下を招き、しばしば治癒しない潰瘍、壊疽、切断のリスクをもたらします。慢性疾患の世界の負担が増加する中、ヘルスケアプロバイダーや製薬会社は、患者の予後を改善するための先進的な治療オプションに注目しています。人口の高齢化、ライフスタイルに関連した危険因子、肥満の増加などが、効果的なCLI治療に対する需要をさらに高めています。さらに、低侵襲血管内治療や再生医療の進歩は、CLI患者に新たな希望をもたらしています。

重症虚血肢の主な治療法は？主要セグメントを探る

CLI治療市場は、血行再建術、薬理学的介入、新興の再生療法など、さまざまな治療アプローチで構成されています。血管形成術やステント留置術などの血管内治療は、CLI患者の血流を回復させるためのゴールドスタンダードであり続けており、新しい薬剤コーティングバルーン技術が長期的な有効性を高めています。バイパス術などの外科的治療も重症例に広く用いられています。抗血小板療法や抗凝固療法を含む薬物治療は、疾患の進行を予防する上で重要な役割を果たしています。さらに、幹細胞治療や遺伝子に基づく治療などの再生医療アプローチは、血管再生や創傷治癒の促進に有望な結果を示しています。遠隔医療とAIによる診断の統合は、早期発見と個別化治療戦略をさらに向上させています。

テクノロジーはCLI治療をどう変えるか？AI、バイオマテリアル、個別化医療の役割

CLI治療分野は、生体材料、AI主導型診断、精密医療における技術革新によって進化しています。AIを搭載した画像診断ツールは、血管の健康状態を分析し、虚血部位をより正確に特定することで、早期発見を強化しています。生体工学による人工血管や組織足場の開発により、血流回復が長期間持続することで治療成績が向上しています。さらに、遺伝子治療と幹細胞移植の進歩は、切断の必要性を減らす潜在的な再生ソリューションを提供しています。ウェアラブルの健康モニタリング・デバイスも、血液循環を追跡する役割を果たし、リアルタイムの患者管理を可能にしています。個別化医療が普及するにつれ、遺伝子や代謝プロファイルに基づくオーダーメイドの治療戦略がCLIの治療効果を向上させています。

CLI治療市場の成長の原動力は？主な市場影響要因

重症虚血肢治療市場の成長を牽引しているのは、疾患有病率の増加、ヘルスケア支出の増加、血管内治療や再生治療の進歩です。血管外科やインターベンショナル・カーディオロジー・プログラムの拡大により、先進的なCLI治療へのアクセスが向上しています。さらに、早期スクリーニングとPADの認知を促進する政府の取り組みが、診断率の向上に寄与しています。価値観に基づくヘルスケアモデルの台頭は、費用対効果の高いCLI治療法の開発を促し、十分なサービスを受けていない人々にとっても治療がより身近なものとなっています。新たな血管再生技術の継続的な研究と世界のヘルスケアインフラの拡大により、CLI治療市場は大きな前進と長期的な成長を遂げる態勢が整っています。

セグメント

DFU治療薬（創傷被覆材、生物製剤、治療機器、抗生物質製剤、その他のDFU治療薬）、DFU治療潰瘍タイプ（神経障害性潰瘍、虚血性潰瘍、神経虚血性潰瘍）、DFU治療エンドユーザー（病院エンドユーザー、外来手術センターエンドユーザー、その他のエンドユーザー）

調査対象企業の例

• Abbott Laboratories
• AnGes, Inc.
• B. Braun Melsungen AG
• Bayer AG
• Boston Scientific Corporation
• Cardiovascular Systems, Inc.
• Cesca Therapeutics（ThermoGenesis Holdings, Inc）
• Cook Medical
• Cynata Therapeutics Ltd
• Eli Lilly and Company
• LimFlow SA
• Medtronic plc
• Micro Medical Solutions
• Mitsubishi Tanabe Pharma Corporation
• Pfizer Inc.
• Pluristem Therapeutics Inc.
• Rexgenero Ltd.
• Sanofi
• Terumo Corporation
• Teva Pharmaceuticals

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Critical Limb Ischemia Treatment Market to Reach US$8.1 Billion by 2030

The global market for Critical Limb Ischemia Treatment estimated at US$5.6 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Wound Care Dressings, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$2.8 Billion by the end of the analysis period. Growth in the Biologics segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 9.8% CAGR

The Critical Limb Ischemia Treatment market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Critical Limb Ischemia Treatment Market - Key Trends & Drivers Summarized

Why Is the Demand for Critical Limb Ischemia Treatment Increasing? Understanding the Rise in Peripheral Artery Disease Cases

The global critical limb ischemia (CLI) treatment market is witnessing rapid growth due to the increasing prevalence of peripheral artery disease (PAD), diabetes, and cardiovascular conditions. CLI is a severe form of PAD that leads to reduced blood flow in the lower extremities, often resulting in non-healing ulcers, gangrene, and amputation risks. As the global burden of chronic diseases rises, healthcare providers and pharmaceutical companies are focusing on advanced treatment options to improve patient outcomes. Aging populations, lifestyle-related risk factors, and the growing incidence of obesity have further fueled the demand for effective CLI therapies. Additionally, advancements in minimally invasive endovascular procedures and regenerative medicine have provided new hope for CLI patients.

What Are the Leading Treatment Options for Critical Limb Ischemia? Exploring Key Segments

The CLI treatment market consists of various therapeutic approaches, including revascularization procedures, pharmacological interventions, and emerging regenerative therapies. Endovascular treatments, such as angioplasty and stent placement, remain the gold standard for restoring blood flow in CLI patients, with newer drug-coated balloon technologies enhancing long-term efficacy. Surgical interventions, including bypass grafting, are also widely used for severe cases. Pharmacological treatments, including antiplatelet and anticoagulant therapies, play a critical role in preventing disease progression. Additionally, regenerative medicine approaches, such as stem cell therapy and gene-based treatments, have shown promising results in promoting vascular regeneration and wound healing. The integration of telemedicine and AI-driven diagnostics is further improving early detection and personalized treatment strategies.

How Is Technology Transforming CLI Treatment? The Role of AI, Biomaterials & Personalized Medicine

The field of CLI treatment is evolving with technological innovations in biomaterials, AI-driven diagnostics, and precision medicine. AI-powered imaging tools are enhancing early detection by analyzing vascular health and identifying ischemic regions with greater accuracy. The development of bioengineered vascular grafts and tissue scaffolds has improved treatment outcomes by providing long-lasting blood flow restoration. Additionally, advances in gene therapy and stem cell transplantation are offering potential regenerative solutions, reducing the need for amputation. Wearable health monitoring devices are also playing a role in tracking blood circulation, enabling real-time patient management. As personalized medicine gains traction, tailored therapeutic strategies based on genetic and metabolic profiles are improving CLI treatment efficacy.

What’s Driving the Growth of the CLI Treatment Market? Key Market Influencers Explained

The growth in the critical limb ischemia treatment market is driven by increasing disease prevalence, rising healthcare expenditures, and advancements in endovascular and regenerative therapies. The expansion of vascular surgery and interventional cardiology programs has improved access to advanced CLI treatments. Additionally, government initiatives promoting early screening and PAD awareness have contributed to higher diagnosis rates. The rise of value-based healthcare models has encouraged the development of cost-effective CLI therapies, making treatment more accessible to underserved populations. With continued research in novel vascular regeneration techniques and expanding global healthcare infrastructure, the CLI treatment market is poised for significant advancements and long-term growth.

SCOPE OF STUDY:

The report analyzes the Critical Limb Ischemia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

DFU Treatment (Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications, Other DFU Treatments); DFU Treatment Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, Neuro-ischemic Ulcers); DFU Treatment End-Use (Hospital End-Use, Ambulatory Surgery Centre End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Abbott Laboratories
• AnGes, Inc.
• B. Braun Melsungen AG
• Bayer AG
• Boston Scientific Corporation
• Cardiovascular Systems, Inc.
• Cesca Therapeutics (ThermoGenesis Holdings, Inc)
• Cook Medical
• Cynata Therapeutics Ltd
• Eli Lilly and Company
• LimFlow SA
• Medtronic plc
• Micro Medical Solutions
• Mitsubishi Tanabe Pharma Corporation
• Pfizer Inc.
• Pluristem Therapeutics Inc.
• Rexgenero Ltd.
• Sanofi
• Terumo Corporation
• Teva Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Critical Limb Ischemia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Peripheral Arterial Disease (PAD) and Diabetes Drives Growth in Critical Limb Ischemia Treatment Demand
  • Rising Aging Population and Associated Vascular Diseases Expands Market Opportunity for CLI Treatment Solutions
  • Advancements in Endovascular Procedures Strengthen the Business Case for Minimally Invasive CLI Treatment Options
  • Surge in Smokers and Obesity Rates Expands Addressable Market for Critical Limb Ischemia Therapies
  • Increasing Focus on Early Detection and Prevention Strategies Propels Growth in CLI Treatment and Management Tools
  • Technological Innovations in Angioplasty and Stenting Devices Enhance Treatment Outcomes and Drive Adoption of CLI Therapies
  • Growing Adoption of Hybrid Surgical Procedures in CLI Treatment Spurs Demand for Advanced Vascular Interventions
  • Rising Demand for Personalized Medicine and Tailored Treatment Plans Accelerates Market Growth for CLI Therapies
  • Surge in Health Insurance Coverage and Healthcare Accessibility Expands the Market for CLI Treatment Solutions in Emerging Economies
  • Integration of Artificial Intelligence and Imaging Technologies in CLI Diagnosis and Treatment Drives Market Innovation
  • Increasing Use of Stem Cell and Regenerative Medicine Technologies in CLI Treatment Generates New Growth Opportunities
  • Rise in Healthcare Spending and Investment in Specialized Vascular Care Expands the Market for CLI Interventions
  • Growing Focus on Post-Surgery Recovery and Rehabilitation Drives Demand for CLI Treatment Solutions with Shorter Recovery Times
  • Regulatory Changes and Advancements in Clinical Guidelines for CLI Treatment Spur Market Adoption of New Therapeutic Options
  • The Emergence of Telemedicine and Remote Monitoring Solutions Expands Market Opportunity for Post-Treatment CLI Care
  • Rising Awareness of CLI and Vascular Health Challenges Accelerates Demand for Educational Campaigns and Screening Programs
  • Increasing Number of Clinical Trials and Research Projects on CLI Treatment Drives Innovation in Therapies and Technologies
  • Growing Emphasis on Non-Surgical Treatment Options Strengthens Demand for Drug Therapies and Endovenous Laser Therapies for CLI
  • Surge in Peripheral Endovascular Interventions for CLI Treatment Generates Opportunities for Cross-Specialty Collaboration in Healthcare
  • Focus on Minimizing Amputation Rates and Improving Limb Salvage Drives Adoption of Advanced CLI Treatment Modalities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Critical Limb Ischemia Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Critical Limb Ischemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Critical Limb Ischemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Wound Care Dressings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Wound Care Dressings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Wound Care Dressings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Therapy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Therapy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Therapy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antibiotic Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antibiotic Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Antibiotic Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other DFU Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other DFU Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other DFU Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centre End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Ambulatory Surgery Centre End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Ambulatory Surgery Centre End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospital End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Neuropathic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Neuropathic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Neuropathic Ulcers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Ischemic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Ischemic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Ischemic Ulcers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Neuro-ischemic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Neuro-ischemic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Neuro-ischemic Ulcers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• JAPAN
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• CHINA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• EUROPE
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Critical Limb Ischemia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Critical Limb Ischemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• FRANCE
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• GERMANY
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Critical Limb Ischemia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Critical Limb Ischemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• INDIA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Critical Limb Ischemia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Critical Limb Ischemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Critical Limb Ischemia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Critical Limb Ischemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030
• AFRICA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Critical Limb Ischemia Treatment by DFU Treatment - Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment - Percentage Breakdown of Value Sales for Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications and Other DFU Treatments for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centre End-Use, Other End-Uses and Hospital End-Use for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Critical Limb Ischemia Treatment by DFU Treatment Ulcer Type - Percentage Breakdown of Value Sales for Neuropathic Ulcers, Ischemic Ulcers and Neuro-ischemic Ulcers for the Years 2015, 2025 & 2030

IV. COMPETITION